Skip to content
Bending the Curve Trial by Trial
?

KEYNOTE-087

A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Phase 2N = 210NCT02453594

Population
Relapsed or refractory classic Hodgkin lymphoma; 210 patients enrolled and treated.
Design
Single-arm phase 2 study of pembrolizumab 200 mg once every 3 weeks in three cohorts: progression after autologous stem cell transplantation and subsequent brentuximab vedotin (cohort 1, n=69); salvage chemotherapy and brentuximab vedotin and ineligible for transplantation because of chemoresistant disease (cohort 2, n=81); transplantation without brentuximab vedotin after transplant (cohort 3, n=60). Response assessed every 12 weeks. Primary endpoints: ORR by central review and safety.
Primary endpoint
ORR
Arms
  • Pembrolizumab (experimental, n = 210): Pembrolizumab 200 mg once every 3 weeks
People
Chen R
Show the numbers
Results reported for KEYNOTE-087
EndpointAnalysisPembrolizumabControlEffect
ORRAll enrolled and treated patients (210)primaryChen 201769% (62.3–75.2%)—Per central review. ORR by cohort: 73.9% (cohort 1), 64.2% (cohort 2) and 70.0% (cohort 3).
CR rateAll enrolled and treated patients (210)primaryChen 201722.4% (16.9–28.6%)—Per central review.
Results reported for KEYNOTE-087
EndpointAnalysisPembrolizumabControlEffect
ORRAll enrolled and treated patients (210)primaryChen 201769% (62.3–75.2%)—Per central review. ORR by cohort: 73.9% (cohort 1), 64.2% (cohort 2) and 70.0% (cohort 3).
CR rateAll enrolled and treated patients (210)primaryChen 201722.4% (16.9–28.6%)—Per central review.
Primary publication: Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125-2132. PubMedDOI

Appears in

Sources

  1. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125-2132.

    PubMedDOI